UCL ADVANCED CENTRE FOR
Biochemical Engineering
In this issue
Visit of HRH The Princess Royal
Launch of the VISION
Senior Executive Programme
Industrial Training Open Day
Facilities fit for the 21st century
Synthetic Biology successes
16 BBSRC Studentships awarded
ISSUE FIVE | JULY 2010
Contents
Editorial
Editorial
2
Foreword by Professor Nigel Titchener-Hooker
Departmental news
3
Welcome to this fifth edition of BioProcessing Matters.
UCL and the Advanced Centre for Biochemical Engineering
have always driven research excellence, and this newsletter
provides a snapshot of just some of the bioprocess leadership
activities currently being undertaken with industrial partners.
Our industry is changing rapidly and in particular we see
a move towards the wider adoption of single-use components
as a route to achieving rapid bioprocess evaluation and
development. We have recognised the trend and are creating a
‘Responsive Bioprocess Training and Research Facility’ within our Advanced Centre
Pilot-Plant. With close industry collaborations this will ensure that we continue to
create the individuals with the right skills for the future and that we can conduct the
most relevant research as this impacts industry.
In May I was delighted to help in the launch of VISION, a series of events, modules
and briefings focused specifically on senior executives in biopharma. The level of
excitement for this venture is clear to see and marks a new avenue for the department
but one which I believes plays very much to our unique strengths in bioprocessing in a
business context.
It is always good to have external recognition of our work and it is especially
pleasing that the teaching prowess of one of our staff, Dr Suzy Farid, known to many
for her excellent work on the MBI ® Quality by Design for Effective Characterisation and
Validation module, was this year officially recognised. Suzy has been awarded a coveted
Exxon-Mobil Royal Academy of Engineering Award for Teaching Excellence. A
national award and richly deserved! Similarly, our students at all levels are a key output
and a reflection of our research and training ethos, be it in terms of their placements
with industry or through awards for leadership. A source of constant re-invigoration,
they continue to set new heights in what they achieve.
Visit of HRH The Princess
Royal to the UCL IMRC
and IDTC in Bioprocessing 5
VISION launch
7
Industrial Training
Open Day
9
Genzyme placement
10
Mammalian Cell Processes
MBI® Module 11
Training and research facilities
fit for the 21st century
12
BBSRC successes
14
Synthetic Biology Grants
15
MBI® course dates 2010–11 16
Prof. Nigel Titchener-Hooker
Head of Department and Director of the Advanced Centre for
Biochemical Engineering
2
Departmental news
CV booklet
Every year, UCL graduates in biochemical engineering
go on to highly successful careers in the bioprocessing
and related sectors.
They enter a wide range of industries in the process
engineering sector, including biopharmaceutical,
biotechnology, environmental control, chemicals,
foods, pharmaceuticals, financial and consulting
services, equipment, design, contracting etc. and,
most recently, in regenerative medicines and the use of
human cells for therapy.
This year we have produced a booklet containing
CVs of our students who will be seeking employment in
2010. If you would like a copy of this booklet, please contact Dr Karen Smith at
karen.smith@ucl.ac.uk.
Vaccine Bioprocess Development and
Commercialisation module wins BBSRC MTI grant
We are delighted to announce that we have
won a BBSRC Modular Training for Industry
(MTI) grant for the development of our
new MBI® module in the area of Vaccines.
The course has been developed in response
to industrial demand and will run on
8–10 December 2010.
It will be suitable to those who wish to increase their knowledge of vaccine
development or who are part of strategic planning of projects. The course will be taught
by a mixture of both academics and industrialists to provide a balance of both the
theoretical with industrial case studies.
Confirmed speakers thus far include:
• Barry Buckland (BiologicB, Wellcome Trust)
• Debbie Drane (Senior VP, CSL)
• David Kirke (Associate Director, ERA Consulting)
• Mary Morry (Assistant Counsel, Merck)
• Sangeetha Sargar (Executive Directors and Operations Lead , Merck)
• Raf Lemmons (Global Fast-Trak Leader, GE)
• Andy Masters (DSP Lead, GE Healthcare)
• Kjell Jansson (Lead Consultant, Projektengagemang)
For further information about the module please contact Dr Tarit Mukhopadhyay at
t.mukhopadhyay@ucl.ac.uk or by telephone (0)20 7679 2762.
3
Royal Academy of Engineering successes
Dr Suzy Farid has won a prestigious Royal Academy of Engineering/Exxon Mobil Award for Excellence in Teaching.
The award recognises her unique contributions to the teaching of bioprocess design to multi-disciplinary groups of
undergraduates and to the close involvement of industry and regulatory expert panels in the delivery of highly relevant
material tacking global healthcare issues.
She said: “Receiving this Royal Academy of Engineering/Exxon Mobil Award is a great honour and it reinforces UCL
Biochemical Engineering’s reputation as a centre of excellence in teaching. I’ d like to dedicate this award to the late Professor
Peter Dunnill who inspired generations to be passionate about biochemical engineering and to pursue excellence in teaching as
well as research. Sincere thanks to my mentors for their continual support and encouragement. And thanks to our students for
their enthusiastic participation in sessions.”
Suzy’s award means the department will receive a package of benefits worth £50,000, including a cheque for £10,000.
While the department is the major beneficiary of the award, the application focuses on the merits of a specific member of
staff. Professor Nigel Titchener-Hooker, Head of UCL Biochemical Engineering, said: “The linking of leading-edge research
with teaching innovations are the hallmarks of Suzy’s academic career. This combination ensures that cohorts of students in
our department gain the latest insights which in turn sets them up for valuable future careers. The award is a recognition of
the passion Suzy displays for her subject and of her dedication. All of the department benefits from that vision and by working
closely with such an inspirational individual.”
We are also delighted to announce that one of our students, Natasha Davie (pictured below), has won the ‘Engineering
Leadership Advanced Award’ from the Royal Academy of Engineering. She said: “I’m really pleased, Biochemical
Engineering is such a diverse and exciting subject and now the Royal Academy of Engineering has given me the opportunity to
explore the many different aspects of my field.”
© UCL Media Services, All Rights Reserved
The Princess Royal arriving at the UCL Faculty of Engineering Sciences being met by the UCL President and Provost,
Prof. Malcolm Grant and the Dean of Engineering Sciences Prof. Bernard Buxton
Visit of HRH The Princess Royal to the
UCL IMRC and IDTC in Bioprocessing
On 12 January HRH The Princess Royal, Chancellor of the University of London, visited the UCL Faculty of Engineering
Sciences to open new facilities and to discuss research and training within the Faculty.
During the visit she met with Professor Nigel Titchener-Hooker FIChemE FREng, Head of Department and Director
of the Innovative Manufacturing Research Centre (IMRC) in Bioprocessing, and Professor Gary Lye FIChemE, Director
of the Industrial Doctorate Training Centre (IDTC) in Bioprocess Engineering Leadership. Professor Titchener-Hooker
described some of the bioprocessing challenges in bringing novel therapies to market such as new types of vaccine and
human cells for therapy. In particular he commented on “the importance of EPSRC support for manufacturing research if the
high level of investment in the biosciences is to lead to wealth creation for the UK”. Professor Lye noted “the critical shortage of
individuals skilled at working at the bioscience-engineering interface” and described the role of the IDTC in training the next
generation of research and industry leaders.
The Princess Royal discussed the need for new vaccines with one of the new lecturers in the UCL Department of
Biochemical Engineering, Dr Tarit Mukhopadhyay. Dr Mukhopadhyay was one of the early Engineering Doctorate (EngD)
graduates from UCL, having worked on a collaborative project between the Department and the UK Health Protection
Agency (Porton Down). During his doctorate Dr Mukhopadhyay applied some of the microscale bioprocessing techniques
pioneered in the IMRC programme to two types of vaccine. The first phase of his EngD helped establish a manufacturing
5
© UCL Media Services, All Rights Reserved
route for a new Meningitis B vaccine. He also applied the same technology to examine improvements in the manufacturing
process for the current licensed Anthrax vaccine. With the Princess Royal he described how since becoming a lecturer in 2008
he has established new research on a range of vaccines including Japanese Encephalitis, Hepatitis A and B and gene based
vaccines. The Princess Royal was also interested to hear about increasing access to vaccines in less developed countries and
was encouraged to hear about the department’s collaboration with the Hilleman Institute, India, and the Wellcome Trust to
facilitate knowledge transfer for vaccine development.
The Princess Royal showed particular interest in the microscale and single-use bioprocessing technologies and their
potential benefits for low cost, small volume responsive manufacture to meet currently unmet medical needs especially in
developing countries.
For more information on the UCL IMRC in Bioprocessing please contact the Director, Professor Nigel TitchenerHooker, at nigelth@ucl.ac.uk. See also http://www.ucl.ac.uk/biochemeng/industry/imrc
For more information about the UCL IDTC in Bioprocess Engineering Leadership please contact the Director,
Professor Gary Lye, at g.lye@ucl.ac.uk. See also http://www.ucl.ac.uk/biochemeng/industry/engd
For more information on vaccine bioprocessing research please contact Dr Tarit Mukhopadhyay at
ucbetkm@ucl.ac.uk). See also http://www.ucl.ac.uk/biochemeng/about/staff/mukhopadhyay
HRH The Princess Royal talking to Prof. Nigel Titchener-Hooker, Prof. Gary Lye and Dr Tarit Mukhopadhyay.
© UCL Media Services, All Rights Reserved.
VISION launch
The inaugural run of our VISION Programme for Senior Executives in the Bioprocess
Industries was met with a real sense of excitement and enthusiasm from all those who
participated.
An A-list of industrial speakers assisted UCL Biochemical Engineering academics,
led by Dr Eli Keshavarz-Moore and Dr Karen Smith, in the delivery and facilitation
of the course that provided invaluable insights into the major challenges faced
at Boardroom and Executive Team level every day. The Programme highlighted
opportunities and creative solutions that can be utilised to tackle those challenges head
on through a series of interactive case studies, discussions and facilitated workshops.
Speakers included Gary Aldam (Harpum), Prof. Steve Arlington (PwC),
Dr Philippe Auclair (Abbott), Prof. Barry Buckland (BiologicB), Michael Carroll
(Carroll Pharma Consulting), Harriet Fear (ERBI), Martyn Postle (Asia Healthcare &
Biotech), Vicki Salmon (IP Asset), Dr Michelle Scott (Unicorn Biologics) and
Dr Neil Weir (UCB Celltech).
Themes covered included:
• Changing Life Cycle and Alternative Business Models
• Advances in Bioscience and Processing &Impact on Company Growth
• Alliances and Partnerships
• Changes in Patenting and Regulations-Impact on Growth and Competitiveness
• Management of Risk
The fourteen delegates included representatives from a broad range of companies,
including Cantabbio, Francis Biopharma, GSK, Lonza, Lupin Pharma, MedImmune,
Pall, Stabilitech, The Automation Partnership and UCB Celltech. The Head of
Bioprocess UK, Mark Bustard, also attended.
Dr Tony Bradshaw, Co Director, HealthTech & Medicines KTN, said: “This
programme is expected to play an important role in helping to deliver the Life Sciences
Business and Leadership Programme recommended in the Office for Life Sciences 2010
Report.”
If you are interested in attending the next core course or one of the future Executive
Briefings, or believe that there is a Senior Executive within your organisation who
would benefit from attendance, please contact Dr Karen Smith, Director of Bioprocess
Leadership at karen.smith@ucl.ac.uk or by telephone at (0)20 7679 4411.
The next VISION event will be a Business Briefing by Prof Steve Arlington
of PriceWaterhouseCoopers (PWC) on ‘Developing drugs the payer can pay’.
This will take place at 5pm on the evening of 16 September and will be followed
by a dinner at the UCL Terrace Restaurant. Bookings can be made by emailing
Elizabeth Barrett at mbi-training@ucl.ac.uk or by using the on-line booking system
(www.ucl.ac.uk/biochemeng/industry/vision). Places cost £50 each.
7
Delegates and UCL staff at the first VISION event.
8
Industrial Training Open Day
Our second Industrial Training Open day was held on 11
March 2010 and attracted fifteen industrialists including
representatives from Biopharm Services, BPL, Immbio, Lonza,
MedImmune,Novasep, Oxford Biomedica and SciTech. We
were also delighted to be joined by Zoe Brown, the Portfolio
Manager for Cross-disciplinary interfaces and Medicines and
Healthcare Sector, EPSRC, and by Alastair Knowles, the UCL
Doctoral Training Manager.
The morning was split into two sessions, one encompassing
all the training activities of the Department – the Industrial
Training Advisory Board (ITAB) – and the other focusing on
the activities of the EPSRC Industrial Doctoral Training Centre
(IDTC) in Bioprocesses Engineering Leadership.
Presentations covered a broad range of areas from senior executive training to post-experience training in Quality
by Design and Vaccine development, to ‘whole bioprocess’ MRes/EngD training and progress on our Responsive
Bioprocessing Facility (see page 12).
A buffet lunch and poster session enabled industrialists to meet our EngD students and discuss their research and its
industry relevance and application. This year’s BPL-sponsored poster prise was awarded to Kristina Kovacs-Schreiner for
her poster entitled ‘Measurement of protein self association behaviour as a determinant of aggregation in bio-processing’
Later in the day industrialists assisted with interviewing a number of excellent undergraduate students for the
prestigious Sir Derrick Roberts Scholarships. The scholarships are awarded to students who can best demonstrate their
understanding of biochemical engineering’s value to society and who can show a clear vision of what they want to achieve
from their degree course in terms of career direction.
The day ended with a well-attended Departmental Team Briefing and Reception.
The Industrial Training Advisory Board (ITAB) meets annually to ensure the relevance of the training programmes
to industry. If you would like to find out more about ITAB please contact Dr Karen Smith, Director of Bioprocess
Leadership, at karen.smith@ucl.ac.uk or by telephone at (0)20 7679 4411.
9
Genzyme placement
Anant Tucker writes: I recently started a sixmonth placement at Genzyme Diagnostics,
having completed a Masters in Biochemical
Engineering with Bioprocess Management at
UCL in August 2009. I secured this placement
through the ECIF* scheme set up last summer
by the university in collaboration with the UK
government, and am based at the company’s
production facility in Allington, Kent. My
work lies principally with the Manufacturing
Support Group, which is responsible for
addressing production issues with the
diagnostic intermediates and critical raw
materials produced here.
One of these is an enzyme used for making cholesterol testing kits, currently produced bacterially at large scale, and the
investigation of some of the issues associated with this process forms the main part of my project. After the initial training
period I have now been given considerable freedom to design experiments and define the project’s direction. Two months
into the placement, I have had the opportunity to design and run model fermentations at 5L scale based on the full-scale
process. Based on my experimental finding, Genzyme will hopefully develop a better understanding of the scaling of
fermentations down to 5L and a broader understanding of the production process, which could be used to support future
process improvements.
The atmosphere at Genzyme is amiable and everyone has been
extremely open and supportive. I have enjoyed my time here so far and
feel like I have learnt much already. I am particularly grateful to several
of my colleagues who have gone out of their way to make my experience
as interesting and beneficial as possible. By the time the placement finishes in August I am sure my knowledge and
experimental skills will have improved greatly and I will have developed a greater understanding of how a manufacturing
operation is run.
My line manager, Darren Ladd, feels that this is a “win-win-win” situation for all three parties involved. “This type of
collaboration benefits the graduate, placement organisation and UCL. It enables the graduate to enhance their experience
and develop their knowledge and skills within a real-time commercial environment. Anant has fitted in well with the
Manufacturing Support team, demonstrating knowledge, confidence and drive for success. In addition, the placement
organisation benefits, as it can enable its permanent staff to gain valuable supervisory experience and UCL benefits by
demonstrating the high calibre of the graduates it is producing.”
* ECIF is the The Higher Education Funding Council for England ‘Economic Challenge Investment Fund’ . Graduates on
the scheme not only benefit from working with companies for between ten and 50 weeks, but also gain access to our highquality MBI® post-experience modules, and acquire the kind of bioprocessing and business skills that will be invaluable to
them in their future careers. For further details contact Dr Karen Smith, Director of Bioprocess Leadership, at
karen.smith@ucl.ac.uk or by telephone at (0)20 7679 4411.
10
Mammalian Cell Processes
(MCP) MBI® Module
Improve your knowledge of mammalian cell processes
Our next MCP module runs on 31 January – 2 Februray 2011.
This module will focus on the following distinctive aspects and challenges involved
in the development of mammalian cell processes, including the underlying technology
of mammalian cell process development, the jump from research to development, the
early process decisions and how they impact on later development, the impact of the
product itself upon the process, economic evaluation and the business challenges and
the impact of cell physiology and metabolic engineering.
Programme
Monday 31 January
• Overview of Mammalian Cell Processes
• Recombinant Protein Expression in Mammalian Hosts
• Cell Banking
• Metabolic Engineering
Tuesday 1 February
• Case Study: Cancer Therapy
• Virus Vaccine Production
• Media Development
• Scale-Up Bench Scale to 2000L
Wednesday 2nd February
• Case Study: From Development to Production
• Development of Protein-Free Processes
• High-Throughput Microwell Approaches to Scale-Up and Cell Line Evaluation
Module Leader: Farlan Veraitch, UCL.
Previous Speakers have included
Jon Dempsey, Invitrogen; Suzanne Farid, UCL; Wyn Forrest-Owen, MedImmune;
Steve Froud, Lonza Biologics; Marcel Kuiper, MedImmune; Julia Markusen,
Merck & Co. Inc.; Carol Marshall, GlaxoSmithKline; Mark Rendall, Lonza Biologics;
Tom Seddon, BioDesign Consultancy; Mark Smales, University of Kent; Anne Stokes,
GlaxoSmithKline.
A networking dinner will be held on the first evening.
The module costs £1300, with a £100 discount if you register and pay before 4 January 2011.
For more information, contact Farlan Veraitch at f.veraitch@ucl.ac.uk or by
telephone at (0)20 7679 2648
11
The MBI Training
Programme is run by
the Department and
comprises a series of
UCL-accredited short
courses in bioprocessing,
designed specifically
for industrialists. They
can be taken as standalone modules or can be
combined for certificate,
diploma or Masters
qualifications. To date
1,000 modules have
been taught to over 700
international delegates, and
more than 200 companies
have participated.
Training and research
facilities fit for the 21st
century
A unique feature of all UCL graduates is their pilot-scale bioprocessing experience. The
hands-on use of pilot-scale equipment and exposure to Standard Operating Procedures
(SOPs) features in all our training programmes, from undergraduate to masters and
doctoral level. This culminates in a series of pilot-plant week activities where teams of
students benefit from the opportunity to participate in the planning and operation
of whole bioprocess sequences. The processes investigated range from antibodies and
plasmid genes to chiral chemicals and pharmaceutical intermediates.
The bioprocess suites in the Advanced Centre for Biochemical Engineering
(ACBE), which are the focus of all these activities, were conceived 15 years ago and
have been the subject of continual upgrades since. Throughout summer and autumn
2010 the latest and most comprehensive phase of refurbishment will occur with the
investment of over £700k in creation of a new Responsive Bioprocess facility. The aim
is to deliver a research and training facility fit for the 21st century. In addition it will
provide an environment and displays that allow us to engage more fully with schools
and the wider public so that we can better communicate the benefits and impacts of the
work we do.
This investment is being made possible with support from UCL following our
recent success in securing EPSRC EngD funding for the Industrial Doctoral Training
Centre (IDTC) in Bioprocess Engineering Leadership. The extent of the work, which
includes a significant expansion in our mammalian cell culture facilities, is shown
opposite. A new meeting and case study room is also being constructed dedicated to the
training needs of the EngD cohort.
The last decade has also seen a major shift across the industry with the widespread
adoption of single-use bioprocess equipment. Initially this was with rocked bioreactors
like the one shown overleaf, and is now extending to disposable solutions for product
recovery and purification. Suzanne Farid has been at the forefront of this ‘disposables
revolution’ with her work on business and operations modelling addressing the
strategic and economic drivers behind adoption of single-use technologies within
companies. In parallel with the ACBE refurbishment we will be working with a
number of companies to embed the practical application of single-use technologies in
all our training and research programmes. This will help ensure that all our graduates
continue to have the relevant and up to date skills necessary to sustain the industry in
the coming years.
If you would like further information on the new facility plans or collaborative
research opportunities within the IDTC please contact the Director, Professor Gary
Lye by email at g.lye@ucl.ac.uk.
12
The Responsive Bioprocessing Facility layout. (Completion planned early 2011.)
13
BBSRC successes
This year the UCL Department of Biochemical
Engineering was awarded four Biotechnology and
Biological Sciences Research Council (BBSRC)
targeted priority PhD studentships in Bioprocessing,
continuing to build upon last year’s success of six studentships. The four awards,
due to start in October 2010, will be awarded to the highest-calibre students to help
them pursue Bioprocess research with the aim of training the next generation of
Bioprocessing leaders.
The new students will carry out research projects to explore novel electrospun
nanofibre adsorbents for bioprocessing, elucidate aggregation mechanisms in
therapeutic antibodies, establish microscale techniques to evaluate the production
and purification of vaccines, and to characterise the engineering aspects of singleuse bioprocess technologies in mammalian cell culture. The BBSRC awards will be
complemented by departmentally funded studentships in the microfluidic investigation
of embryonic stem cell process development, and in the improved protein production
and secretion in Pichia pastoris.
Projects, supervisors and collaborators include: ‘Characterisation of electrospun
nanofibre adsorbents for bioprocessing’ (Daniel G. Bracewell (UCL) and Bob Stevens
(RAL)); ‘Molecular mechanism of human antibody aggregation in solution (Stephen
Perkins (UCL), and Paul Dalby (UCL)); ‘Micro-scale evaluation of the production
and purification of vaccines’ (Tarit Mukhopadhyay (UCL)) and ‘Engineering
characterisation of disposable bioprocess technology for the establishment of novel
scale-up approaches in mammalian cell culture’ (Martina Micheletti (UCL) and
Dr Andrea Ducci (King's College London)).
Additionally, this year saw a successful application to the BBSRC for continued
support of our MSc Biochemical Engineering programme. Training in the area of
bioprocessing remains a priority for BBSRC in relation to both the Bioprocessing
Research Industry Club (BRIC) and also the new strategic area of Industrial
Biotechnology. The new award of £371k provides the equivalent of four fully funded
studentships per annum for the next four years. The award can be used in a flexible
manner to encourage recruitment in areas with particular skills shortages and to
facilitate industry collaborative Masters projects. The UCL MSc is the original taught
course in the subject area and has now been running continuously for over 50 years.
The current intake comprises 33 students. It provides the necessary interdisciplinary
training to enable chemical engineers and life scientists to engage in the bioprocess
industries. Developments over the next three years will see new material introduced
in the areas of Industrial Biotechnology and in vaccine bioprocessing. New handson practical material will also be introduced to make the link between microscale
bioprocess experimentation and large scale verification in the UCL bioprocess pilot
plant.
For further information, contact Dr Dan Bracewell by email at d.bracewell@ucl.ac.uk.
14
Synthetic Biology grants
Two research grants on synthetic biology and
microfluidics were won by Dr Nicolas Szita
and collaborators. A first EPSRC grant (five
years’ duration) will link UCL Biochemical
Engineering with collaborators from the
Universities of Edinburgh, Leeds, Sheffield
and Imperial College. The aim is to identify
and overcome key challenges associated with the manufacture and characterisation
of bioparts for synthetic biology applications and to use the flexible funding scheme
for targeted proof-of-concept studies towards that aim. The second grant is a
European Science Foundation (ESF) EuroSYNBIO grant (“Synthetic Biology To
Obtain Novel Antibiotics and Optimized Production Systems”, SYNMOD, three
years’ duration) and brings together European collaborators from the Universities
of Groningen, Tübingen and Regensburg, ETH Zurich and the Organisation for
International Dialogue and Conflict Management in Austria. The consortium will
apply a comprehensive synthetic biology approach to the design and production of
novel antibiotic molecules. UCL Biochemical Engineering is funded via the BBSRC
and EPSRC in this consortium and will develop parallelised microfluidic bioreactors
for the rapid acquisition of design-relevant gene expression parameters in the required
statistical depth. The project will also link with the Industrial Doctoral Training
Centre “Bioprocess Engineering Leadership” of the Department of Biochemical
Engineering.
For more information on EuroSYNBIO, see http://tinyurl.com/364rhxb. For
further details contact Dr Nicolas Szita,Senior Lecturer in Biochemical Engineering, at
n.szita@ucl.ac.uk or by telephone at (0)20 7679 4418.
15
Contacts
Research Sponsors:
Dr Karen Smith
Director of Bioprocess
Leadership
+44 (0)20 7679 4411
karen.smith@ucl.ac.uk
MBI®:
Miss Liz Barrett
MBI® Manager
+44 (0)20 7679 1316
mbi-training@ucl.ac.uk
Professor Nigel
Titchener-Hooker
+44 (0)20 7679 3796
nigelth@ucl.ac.uk
BiCE, Engineering
Doctorate in Bioprocess
Leadership, IMRC
in Bioprocessing and
Industrial Doctoral
Training Centre for
Bioprocess Leadership
(IDTC)
Professor Gary Lye
+44 (0)20 7679 7942
g.lye@ucl.ac.uk
MBI® course dates 2010–11
Principles of Fermentation Processes: 4 – 6 October 2010
Rapid Fermentation Process Design: From Development to Manufacture:
18 – 20 October 2010
Challenges & Opportunities in Industrial Biotechnology: Biocatalysis and
Synthetic Biology: 1 – 3 November 2010
Primary Recovery: 15 – 18 November 2010
Chromatography: 29 November – 2 December 2010
Vaccines Bioprocessing Development: 8 – 10 December 2010
Mammalian Cell Processes: 31 January – 2 February 2011
Stem Cell and Regenerative Medicine Bioprocessing: 21 – 23 February 2011
Quality by Design: 28 February – 3 March 2011
Design of Experiments for Bioprocess Optimisation: 14 – 16 March 2011
Effective Biopharmaceutical Development & Manufacture: 9 – 11 May 2011
Bioprocess Design & Economic Evaluation: 6 – 9 June 2011
Bioprocess Facility Design: 20 – 23 June 2011
For more information, email mbi-training@ucl.ac.uk
Work with us
The UCL Advanced Centre for Biochemical Engineering actively encourages and
fosters long-term research partnerships between its academics and sponsors for mutual
benefit. We facilitate interaction in a range of ways, such as sponsor visits, industrial
advisory boards, Bioprocess Briefings, industrial placements for graduate students
and the MBI® Programme. Over 60 industrial and academic experts contribute to our
MBI® activities. If you would like further information, please contact the appropriate
member of staff listed to the left.
RegenMed Bioprocessing
Professor Chris Mason
+44 (0)20 7679 0140
chris.mason@ucl.ac.uk
16